

NN3201, an IND-enabling study stage multimodal, cKIT-targeting ADC for SCLC, GIST, and AML



ONCOLOGY	Non-Clinical
Product Type	cKIT-targeting fully human monoclonal IgG with site specific linker and MMAE at DAR 4
Indication	Small cell lung cancer, GIST, AML, Systemic Mastocytosis
Target	cKIT (stem cell factor receptor, CD117)
MoA(Mechanism of Action)	<p>Kills tumor cells and inhibits growth via multiple mechanisms:</p> <ul style="list-style-type: none"> • Targeted delivery of toxic payload in cKIT+ cancers, effectively treating both cKIT wildtype and/or activating mutation-driven tumors • Increasing native tumor immune response by improving the tumor microenvironment
Competitiveness	NN3201 is a first-in-class cKIT ADC with picomolar binding affinity, no off-target binding, no observed immunogenicity, and an excellent preliminary therapeutic window of 20X in rodents.
Development Stage	IND-enabling (IND planned in 4Q 2023)
Route of Administration	Parenteral - Intravenous